Eag1 channels as potential early-stage biomarkers of hepatocellular carcinoma
(Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - September 20, 2016 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
(Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - September 12, 2016 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
New targeted treatments for non-small-cell lung cancer & ndash; role of nivolumab
(Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - July 31, 2016 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Neutralizing activities of human immunoglobulin derived from donors in Japan against mosquito-borne flaviviruses, Japanese encephalitis virus, West Nile virus, and dengue virus
(Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - July 6, 2016 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Guanine nucleotide exchange factor H1 can be a new biomarker of melanoma
(Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - July 4, 2016 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Effects of fucoidan from Fucus vesiculosus in reducing symptoms of osteoarthritis: a randomized placebo-controlled trial
(Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - May 25, 2016 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature
Conclusion: A complete response to therapy without a single attack during treatment was reported in 76.5% of patients on anakinra treatment and in 67.5% of patients during canakinumab treatment. In patients with established type AA amyloidosis, anti-IL-1 treatment can reverse proteinuria. Anti-IL-1 therapy seems to be a safe and effective alternative for patients with FMF who do not respond to or cannot tolerate colchicine. Keywords: familial Mediterranean fever, interleukin-1, amyloidosis, colchicine (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - April 3, 2016 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Anti IL 1 treatment in FMF
van der Hilst JC, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - April 3, 2016 Category: Biochemistry Source Type: research
Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers
This study indicates that routine monitoring of drug level and ADAbs is cost-beneficial in clinical practice, thereby improving the decision-making process in using TNF-α blockers. Keywords: anti-TNF drugs, anti-drug antibodies, trough level measurement (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - April 1, 2016 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Cost effectiveness of measuring serum drug concentration and antibodies
Laine J, Jokiranta TS, Eklund KK, Väkeväinen M, Puolakka K (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - March 31, 2016 Category: Biochemistry Source Type: research
Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years
Conclusion: The efficacy of TCZ in patients with RA refractory to disease-modifying drugs, including anti-tumor necrosis factor blockade and RTX, is sustained over 3 years. TCZ confers a good safety profile in the long term even in patients who previously developed adverse events to other rheumatic drugs. In the long run, there is no statistically significant deterioration in lipid profile during treatment with TCZ.Keywords: tocilizumab, rheumatoid arthritis, refractory rheumatoid, long term, efficacy, safety, tolerability (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - March 21, 2016 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Tocilizumab in rheumatoid arthritis
Farah Z, Ali S, Price-Kuehne F, Mackworth-Young CG (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - March 21, 2016 Category: Biochemistry Source Type: research
Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab
Maurizio Benucci,1 Francesca Meacci,2 Valentina Grossi,2 Maria Infantino,2 Mariangela Manfredi,2 Emanuele Bellio,2 Valerio Bellio,2 Francesca Li Gobbi,1 Laura Bazzichi,3 Paolo Moscato,4 Dario Caputo,4 Gianantonio Saviola,5 Rossella Talotta,6 Piercarlo Sarzi-Puttini,6 Fabiola Atzeni71Rheumatology Unit, Ospedale San Giovanni di Dio, Florence, Italy; 2Allergology and Immunology Laboratory, Ospedale San Giovanni di Dio, Florence, Italy; 3Rheumatology Unit, University of Pisa, Pisa, Italy; 4Internal Medicine and Rheumatology Unit, University of Salerno, Salerno, Italy; 5Rheumatology Unit, Salvatore Maugeri Foundation, Mantua, I...
Source: Biologics: Targets and Therapy - March 10, 2016 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Rheumatoid arthritis patients treated with tocilizumab
Benucci M, Meacci F, Grossi V, Infantino M, Manfredi M, Bellio E, Bellio V, Li Gobbi F, Bazzichi L, Moscato P, Caputo D, Saviola G, Talotta R, Sarzi-Puttini P, Atzeni F (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - March 10, 2016 Category: Biochemistry Source Type: research
Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab
Jill MV Petkau, Bertus Eksteen Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Abstract: Inflammatory bowel disease (IBD) encompasses a cluster of different disease phenotypes which are broadly classified into ulcerative colitis and Crohn's disease. Disease pathogenesis is driven by abnormal host immune responses to their resident gut microbiome in genetically susceptible individuals. Clinical disease features and outcomes are heterogenous and not unexpected as over 163 genetic loci are associated with disease susceptibility, and there are great variability...
Source: Biologics: Targets and Therapy - March 8, 2016 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
